-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Top Ten News Stories of Shijiazhuang Sihua Pharmaceutical Group in 2023
Category:
发布时间：2024-01-12
【概要描述】
Recording the annals of development and feeling the pulse of the times, the list of the Group’s Top Ten News Stories—selected by the editorial team of “Si Yao Ren” at Shijiazhuang Sihua Pharmaceutical Group—was recently announced.
Recording the annals of development and sensing the pulse of the times. Recently, the list of the Group’s Top Ten News Stories, selected by the editorial team of “Siyao People” at Shijiazhuang No. 4 Pharmaceutical Group, was announced.
The Group’s operational development has reached an all-time high.
In 2023, the Group embarked on a new journey of innovation and transformation, leveraging its deep-rooted strengths to achieve breakthroughs in development. Key financial indicators reached record highs in the Group’s history, marking a new milestone in high-quality, innovation-driven growth. Throughout the year, the number of newly approved and filed products led the industry, further solidifying the Group’s position as a leader in intravenous solutions. Meanwhile, the Group’s competitive advantages in areas such as aqueous injections, oral formulations, active pharmaceutical ingredients, and pharmaceutical packaging materials continued to strengthen. The dual-circulation strategy gained momentum, project construction progressed efficiently, and these efforts provided strong support for the Group’s rapid ascent among the top 100 pharmaceutical companies.
The Group Leads the Industry in Generic Drug R&D Efficiency
In 2023, the Group’s robust R&D efforts culminated in a concentrated “harvest period” of innovative development, with a total of 88 new products receiving approval—more than double the number of innovations achieved in 2022. Notably, products such as stearic acid dry suspension and its active pharmaceutical ingredient, as well as pentoxifylline sustained-release tablets, were among the first in China’s industry to receive regulatory approval. The emergence of these new products has laid a solid foundation for the Company to optimize its product portfolio and enhance market accessibility.
The Group has won bids for all products in the 8th and 9th rounds of national centralized drug procurement.
In 2023, all 12 specifications of the nine products in the eighth and ninth rounds of national centralized drug procurement in which the Group participated were successfully selected. Specifically, five products—agathrombopag injection, ornidazole injection, metronidazole injection, felodipine II sustained- and controlled-release tablets, and mecobalamin injection—covering seven specifications, won bids in the eighth round; while four products—azithromycin dry suspension, urapidil hydrochloride injection, teicoplanin phosphate for injection, and citicoline sodium injection—covering five specifications, secured contracts in the ninth round.
The Group’s 600-million-bag-capacity smart and digital infusion workshop has been completed and put into operation.
In 2023, the Group completed and put into operation a smart, digital, upright soft-bag infusion production workshop with an annual capacity of 600 million bottles (or bags). Designed and built to world-class standards with the goal of becoming a “Lighthouse Factory,” the facility incorporates the latest integrated design principles and features state-of-the-art automated, digital, and intelligent equipment along with cutting-edge IoT technologies. It is among the most advanced digitally and intelligently equipped production facilities in China’s industry today, significantly accelerating the Group’s transition from traditional manufacturing to smart manufacturing.
The Group has been ranked among China’s Top 100 Pharmaceutical Companies for 10 consecutive years.
In 2023, the Group once again ranked among the “Top 100 Chinese Pharmaceutical Companies” for the tenth consecutive year and was recognized as a “Best Pharmaceutical R&D Pipeline Enterprise” for the fourth time in a row. Guided by the overarching principle of innovative, high-quality development, the Group aligns its efforts with national strategies and market demands, continuously intensifying its innovation initiatives. It strategically integrates the innovation chain with the industrial value chain, leveraging the former to enhance the latter, and efficiently promotes the coordinated development of its high-end, complex generic drugs, innovative medicines, active pharmaceutical ingredients, and pharmaceutical packaging materials segments. As a result, the company’s scale and market influence have steadily grown.
The Group Recognized as a National Quality Benchmark
The Group’s “21235” risk-control model for parameter-based release, which ensures the quality and safety of pharmaceutical products, has been successfully recognized as a National Quality Benchmark, making it the only pharmaceutical manufacturer nationwide to receive this honor in 2023. The Group places paramount importance on drug quality and has pioneered and established the “21235” risk-control model based on parameter-based release. By leveraging automated, information-driven, and intelligent quality-management tools, the Group continuously refines its quality-management system, achieving integrated, closed-loop quality control across the entire value chain—from R&D to manufacturing—and thereby setting a benchmark for high-quality development in the industry.
The Group Celebrates the 75th Anniversary of Its Founding
Seventy-five years of weathering storms and forging ahead have culminated in remarkable achievements. In 2023, the Group celebrated the 75th anniversary of its founding. Entering a new era, the Group has aligned itself with national development strategies and market demands, strategically integrating innovation into the industrial value chain. Committed to the research, development, and production of high-quality “Made-in-China” pharmaceuticals, the Group has ushered in a new phase of iterative product development, encompassing specialty and high-end complex generic drugs, innovative medicines, improved new drugs, active pharmaceutical ingredients, biologics, and pharmaceutical packaging materials. This has accelerated the Group’s growth trajectory, significantly enhancing its scale, innovation capacity, brand strength, and market influence. As a result, the company has successfully transformed from a business once dominated by a single injectable product to a diversified player across the entire pharmaceutical value chain, earning prestigious national designations such as National High-Tech Enterprise, National Model Enterprise for Technological Innovation, Best Industrial Enterprise for Pharmaceutical R&D Product Lines in China, and National Quality Benchmark Enterprise.
The Group Has Established Strategic Partnerships with Eight Universities
In 2023, the Group accelerated the integration of industry and education, entering into strategic cooperation agreements with eight domestic universities. This has elevated efforts in cultivating high-level research and skilled talent, as well as in developing innovative drug R&D and industrialization expertise, to new heights. Eight universities, including Hebei Normal University, Lanzhou University, North China University of Science and Technology, and Qingdao University of Science and Technology, have established off-campus internship and practical training bases under the Group’s initiative, creating diversified co-construction platforms. Together, they are engaging in in-depth, pragmatic collaboration on major scientific and technological breakthroughs, the cultivation of high-end talent, the commercialization of research outcomes, and employment and internship opportunities, thereby promoting mutually beneficial, win-win outcomes through enhanced university–enterprise partnerships.
Guangxiang Pharmaceutical Group Recognized as a National Green Factory
In 2023, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of the Group, was included in the Ministry of Industry and Information Technology’s 2022 Green Manufacturing List and recognized as a National Green Factory, becoming the Group’s second such facility nationwide. Guided by the new development philosophy, Guangxiang Pharmaceutical has placed the construction of a resource-conserving, environmentally friendly, modern pharmaceutical enterprise at the forefront of its corporate strategy. The company is vigorously developing a green pharmaceutical system that is technology-driven, eco-friendly, and resource-efficient. By implementing initiatives to integrate information technology with industrialization and to drive innovation, Guangxiang Pharmaceutical is committed to building an efficient, clean, low-carbon, and circular green factory, thereby establishing itself as a leading exemplar of energy-saving and environmentally responsible enterprises in the industry.
The Group is authorized to conduct independent title evaluations.
The Group is the first enterprise in Shijiazhuang City to be granted autonomous authority to conduct professional title evaluations at or below the senior level for food and drug engineering. To better attract, retain, and make effective use of talent, Shijiazhuang has focused on local industrial innovation hubs and industry-leading enterprises, actively guiding eligible organizations to independently carry out title evaluations. By placing the decision-making power over talent selection and utilization squarely in the hands of enterprises—allowing them to set their own evaluation criteria and basing promotions on performance—the city has achieved an organic alignment among talent assessment, development, deployment, and incentive mechanisms at the employer level. Since the implementation of this policy, the Group has, through its autonomous evaluation process, conferred professional technical titles on a total of 55 employees.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091